|
|
||||||||

*
Nexstar Pharmaceuticals, Boulder, CO 80301; and
Division of Allergy and Clinical Immunology, University of Colorado Health Sciences Center, Denver, CO 80262
While T cells have been clearly implicated in a number of disease
processes including autoimmunity, graft rejection, and atypical immune
responses, the precise Ags recognized by the pathogenic T cells have
often been difficult to identify. This has particularly been true for
MHC class II-restricted CD4+ T cells. Although such cells
can be demonstrated to have undergone clonal expansion at sites of
pathology, they are frequently difficult to establish as stable T cell
clones. Furthermore, in general, larger peptides in higher
concentrations are required to stimulate CD4+ T cells than
CD8+ T cells, which makes some of the techniques developed
to identify CD8+ T cell Ags impractical. To circumvent some
of these problems, we developed a model system consisting of two parts.
The first part involves the construction of an indicator T cell
hybridoma expressing a chimeric TCR comprised of murine constant
regions and human variable regions specific for influenza hemagglutinin
307319 presented by DR4. The second part consists of a library of
fibroblasts each expressing multiple peptides as amino terminal
covalent extensions of the ß-chain of HLA-DR4 (DRA1*0101, DRB1*0401).
Using this model system, we screened
100,000 peptides and identified
three novel peptides stimulatory for the HA1.7 TCR. While there is some
convergence at residues known to be important for T cell recognition,
all three peptides differ markedly from each other and bear little
resemblance to wild-type hemagglutinin 307319.
This article has been cited by other articles:
![]() |
Z. Zavala-Ruiz, E. J. Sundberg, J. D. Stone, D. B. DeOliveira, I. C. Chan, J. Svendsen, R. A. Mariuzza, and L. J. Stern Exploration of the P6/P7 Region of the Peptide-binding Site of the Human Class II Major Histocompatability Complex Protein HLA-DR1 J. Biol. Chem., November 7, 2003; 278(45): 44904 - 44912. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |